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We present three patients with intrathoracic malignant neurogenic tumor. Two lesions showed no sign of invasion
into adjacent structures, while the third lesion extended to the intraspinal canal with vertebral involvement.
Although all three lesions were completely excised, each patient relapsed within 1 year of the initial treatment.
One patient with local recurrence underwent radiation therapy, but the recurrent tumor continued to progress.
Chemotherapy was subsequently performed. Two patients with distant metastases also received chemotherapy.
Because there is no effective chemotherapeutic regimen for intrathoracic malignant neurogenic tumor, all three
patients received high-dose chemotherapy followed by hematopoietic stem cell transplantation. Although the
relapsed lesions temporarily regressed after treatment, all three patients showed disease recrudescence and
ultimately died of their disease. A comparison of the intrathoracic malignant neurogenic tumors and the benign
neurogenic tumors resected at our institution revealed no meaningful differences distinguishing malignant from
benign neurogenic tumors prior to surgery.
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Neurogenic tumor is a common intrathoracic neoplasm,
representing approximately 20% of all adult and 35% of
all pediatric mediastinal neoplasms [1]. Among these
cases, malignant neurogenic tumor (MNT) of the thorax
is rare. Although its overall incidence remains unclear, it
likely accounts for less than 1% to 2% of mediastinal
neurogenic tumors [2]. In cases of MNT, radical surgical
resection is necessary and is a positive prognostic factor;
however, the overall survival is poor because of local and
distant relapses. The utility of adjuvant chemotherapy or
radiotherapy is unclear [1-6].
We report three cases of intrathoracic MNT treated
with surgery. Additionally, we present a comparison of the
clinical characteristics and outcomes of these patients and* Correspondence: surg3kawaguchi@yahoo.co.jp
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resected at our institution.
Case presentation
Case 1
An abnormal shadow was detected on a chest radio-
graph in a 22-year-old male. Chest computed tomog-
raphy (CT) and magnetic resonance imaging (MRI)
revealed a posterior mediastinal tumor (Figure 1A,B).
The patient was asymptomatic and had no signs of
intraspinal canal extension on the imaging studies. He
underwent surgical resection of the lesion. The oper-
ation was initially performed as video-assisted thoracic
surgery (VATS), but the surgical approach was converted
to a thoracotomy because the tumor was tightly attached
to the chest wall. The tumor was excised completely
(operative time: 2 h and 45 min; blood loss: 100 ml).
Microscopically, the tumor consisted of two areas. One
was a solid or isolated growth of oval primitive cells withs is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Diagnostic exam results for case 1. Chest enhanced CT (A) and T2-weighted MRI (B) showed a well-defined and ovoid mass located
in the paravertebral sulcus without invasion of the vertebral body or intraspinal canal. The microscopic appearance of the area with a solid
growth of primitive cells is shown (C). The lesion was highly cellular (low-power view). The tumor nest was composed of primitive cells with
round or oval hyperchromatic nuclei and scant cytoplasm (high-power view).
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(Figure 1C). The second was a diffuse growth of large
polygonal cells with ganglion cell differentiation and
prominent Schwannian stroma, which was regarded as
a ganglioneuroma. Based on these characteristics, the
tumor was diagnosed as a ganglioneuroblastoma.
The patient received postoperative radiotherapy as an
adjuvant treatment, but it was discontinued halfway
through when multiple bone metastases were identified.
Subsequently, chemotherapy consisting of cisplatin (25
mg/m2 on days 1 to 5), cyclophosphamide (1,200 mg/m2
on days 1 and 2), vincristine (1.5 mg/m2 on day 1), and
pirarubicin-doxorubicin (40 mg/m2 on day 3) was admin-
istered. However, progressive disease was demonstrated
after 3 cycles of this regimen. Next, unrelated cord blood
stem cell transplantation was carried out after a myeloa-
blative conditioning regimen (etoposide: 500 mg/m2 on
day −7; thiotepa: 180 mg/m2 on days −7, −6, and −5; total
body irradiation: 2 Gy × 2 on days −3, −2, and −1). After
this treatment, the bone metastases had regressed, and the
patient was stable for approximately 1 year. Multiple
bone metastases relapsed 18 months after the oper-
ation. High-dose chemotherapy comprising flutamide
(30 mg/m2 on days −6, −5, and −4) and melpharan
(100 mg/m2 on days −3 and −2) was performed
followed by autologous peripheral blood stem celltransplantation (auto-PBSCT). Unfortunately, the treat-
ment produced minimal response, and the patient died 24
months after surgery.Case 2
An abnormal shadow was detected on a chest radio-
graph in a 42-year-old female; a posterior mediastinal
tumor was revealed on chest CT and MRI (Figure 2A,B).
The patient was asymptomatic and did not suffer from
neurofibromatosis type 1. She had no signs of intraspinal
canal extension on the imaging studies. She underwent an
operation via VATS. The tumor did not invade the sur-
rounding organs and was completely excised (operative
time: 3 h and 5 min; blood loss: 98 ml). Microscopically,
the tumor consisted of spindle cells showing a fascicular
growth pattern; they had wavy nuclei and eosinophilic
cytoplasm. Within these overtly malignant areas, numer-
ous rhabdomyoblastic cells and a neurofibroma region
were seen (Figure 2C). On immunohistochemistry, spindle
cells were positive for S-100 and negative for desmin,
while rhabdoid cells were positive of desmin and myo-
genin and negative for S-100. Based on these histological
and immunohistochemical features, a diagnosis of malig-
nant peripheral nerve sheath tumor with heterologous
rhabdomyoblastic differentiation was made.
Figure 2 Diagnostic exam results for case 2. Chest unenhanced CT (A) and T2-weighted MRI (B) showed a well-defined and round mass
located in the paravertebral sulcus without invasion of the vertebral body or intraspinal canal. The microscopic appearance of the tumor is shown
(C). It was a hypercellular, fascicular spindle cell neoplasm; the cells within the lesion had tapering nuclei and pale, indistinct cytoplasm
(low-power view). Within these overtly malignant areas, numerous large, bright eosinophilic rhabdomyoblasts were seen (high-power view).
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adjuvant treatment (50 Gy). Multiple bone and lung me-
tastases were revealed 14 months postoperatively. High-
dose chemotherapy comprising carboplatin (400 mg/m2
on days −7, −6, −5, and −4), etoposide (15 mg/kg on
days −5 and −4), and melpharan (90 mg/m2 on days −3
and −2) was performed followed by auto-PBSCT. After
the treatment, the metastases regressed, and the patient
was stable for 9 months. Lung metastases relapsed 25
months after the operation. Chemotherapy consisting of
doxorubicin (20 mg/m2 on days 1 to 3) and ifosfamide
(2 g/m2 on days 1 to 3) was administered. The regimen
achieved a sustained partial response, and 5 cycles were
performed, which reached the maximum dosage limit for
doxorubicin. Progressive disease was noted 36 months
postoperatively. Chemotherapy comprising dacarbazine
(250 mg/m2 on day 1) and ifosfamide (2 g/m2 on days 1
to 3) was administered. However, the regimen did not
produce a response, and the patient died 42 months
postoperatively.
Case 3
A posterior mediastinal tumor was detected on chest
CT in a 17-year-old male without signs of neurofibroma-
tosis type 1. Both chest CT and MRI revealed intraspinalcanal extension (Figure 3A,B). Because the tumor was
small and the patient was asymptomatic, the lesion was
left untreated at the previous hospital. Six months after
its initial detection, the tumor increased in size, and the
patient was referred to our hospital. He was experien-
cing chest pain, and his chest CT showed a huge, hetero-
geneous mass extending to the intraspinal canal with
involvement of adjacent vertebrae (Figure 3C). A CT-
guided transthoracic biopsy of the tumor revealed malig-
nant neurogenic tumor, and surgery was performed.
First, a fourth to fifth hemilaminectomy was performed
by the neurosurgical team. The tumor was released
without spinal cord injury. Next, the intrathoracic
component was removed via VATS performed by the
thoracic team. The lesion was not disseminated, and
pleural effusion was negative on intraoperative cy-
tology. It was possible to completely remove the tumor
with wedge resection of the adjacent lung (operative
time: 8 h and 19 min; blood loss: 840 ml). Microscopic-
ally, the tumor was composed of short spindle cells
showing a fascicular growth pattern; it had cellular and
more myxoid areas. Polygonal cells were also seen. The
tumor cells had eosinophilic cytoplasm, wavy hyper-
chromatic nuclei, and high mitotic activity (20 to 30
cells/10 HPF; Figure 3D). On immunohistochemistry,
Figure 3 Diagnostic exam results for case 3. Chest enhanced CT (A) and T2-weighted MRI (B) showed a well-defined and ovoid mass located
in the paravertebral sulcus. The tumor extended into the spinal canal. Six months after initial detection of the tumor, chest enhanced CT (C)
showed a huge, heterogeneous mass extending into the intraspinal canal with involvement of adjacent vertebrae. The microscopic appearance
of the tumor is shown (D). The tumor was a highly cellular malignant spindle cell neoplasm that contained alternating cellular and more myxoid
areas (low-power view). The tumor cells had eosinophilic cytoplasm, wavy hyperchromatic nuclei, and high mitotic activity (high-power view).
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and negative for actin, desmin, and keratin. Based on
these morphologic features and the anatomic location,
a diagnosis of high-grade malignant peripheral nerve
sheath tumor was made.
The patient developed local recurrence 3 months post-
operatively. Thoracic radiotherapy (60 Gy) was performed,
but the recurrent tumor continued to progress; pleural
dissemination developed. Subsequently, high-dose chemo-
therapy comprising carboplatin (400 mg/m2 on days −7
and −6), etoposide (15 mg/kg on days −7, −6, −5, and −4),
and melpharan (90 mg/m2 on days −7 and −6) was per-
formed, followed by auto-PBSCT. This treatment achieved
a partial response, and for a time the patient remained
stable with maintenance therapy of doxorubicin alone (50
mg/m2). Tumor regrowth was revealed 24 months postop-
eratively. At this time, high-dose chemotherapy with fluta-
mide (30 mg/m2 on days −7, −6, −5, −4, −3, and −2),
melpharan (70 mg/m2 on days −7 and −6), and ATG (2.5
mg/kg on days −5, −4, −3, and −2) was performed,
followed by allogeneic peripheral blood stem cell trans-
plantation. Although a partial response was temporarily
achieved, the recurrent tumor grew again; the patient died
35 months after the operation.Comparison of patients with malignant and benign
neurogenic tumors
Descriptions of the three patients with MNTs and the 21
patients with BNTs resected at our institution from 2000
to 2010 are provided in Table 1. Among clinical charac-
teristics, no differences were seen between the two
groups. In contrast, the prognosis for the two groups
was completely different. All patients with BNT are alive
without recurrence after resection, while three patients
with MNT died of their disease.
Three patients with MNT did not receive combined
positron emission tomography/computed tomography
using the tracer F-18-fluorodeoxyglucose (FDG-PET/CT)
before operation. On the other hand, 7 patients out of 21
patients with BNT received FDG-PET/CT before oper-
ation. Among them, abnormal FDG uptake was revealed
in five patients. Because the sample size was small and we
did not have the data of MNT, we could not compare the
FDG-PET/CT findings between MNTand BNT.
Discussion
Neurogenic tumors are generally grouped into two cat-
egories: those of nerve sheath origin and those of sympa-
thetic ganglia origin. Nerve sheath tumors are common
Table 1 Patient characteristics in the benign and
malignant neurogenic tumor groups
BNT (n = 21) MNT (n = 3)
Gender (male/female) 13/8 2/1
Age (years) 52 ± 18 (15 to 72)a 27 ± 14 (17 to 43)a
Symptom (yes/no) 2/19 1/2
Location PM: 16 PM: 3
Middle: 1
CW: 4








Surgical approach VATS: 18 VATS: 1
VATS + Post: 2 VATS→Open: 1
Open: 1 VATS + Post: 1
Prognosis Alive without Rec: 21 Died of tumor: 3
BNT, benign neurogenic tumor; MNT, malignant neurogenic tumor; PM,
posterior mediastinal; Middle, middle mediastinal; CW, chest wall; VATS,
video-assisted thoracic surgery; Post, posterior approach; Open, thoracotomy;
Rec: recurrence. aMean ± standard deviation (range).
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in children. Both types have malignant counterparts.
Neurogenic tumors represent approximately 30% of all
mediastinal neoplasms; most are BNTs, which have a
good prognosis after resection [1]. Intrathoracic MNTs
are rare, and few studies have described their clinical
characteristics or outcomes.
We treated three patients with intrathoracic MNTs:
two of nerve sheath origin and one of sympathetic gan-
glia origin. Although the three lesions were surgically ex-
cised, each patient relapsed within 1 year following the
initial treatment. The first relapse was systemic in two
patients and local in one patient. The patient with local
recurrence underwent radiotherapy, which was unsuc-
cessful in stopping the tumor growth. The other two pa-
tients received radiotherapy as an adjuvant treatment, but
they had distant metastases and ultimately died of their
disease. Generally, adjuvant radiotherapy is recommended
after MNT resection to improve local control [4-6]. How-
ever, there is insufficient evidence regarding the efficacy of
radiotherapy for MNT. While some papers have reported
effective treatment with radiotherapy [7,8], it did not ap-
pear to improve the outcomes in our cases.
All three patients were treated with chemotherapy after
recurrence was detected. There is no standard chemother-
apeutic regimen for intrathoracic MNT, so the patients
underwent chemotherapy based on regimens for neuro-
blastoma [9] or other malignant soft tissue tumors [10,11].
In all cases, their responses were insufficient. Subsequently,each patient underwent high-dose chemotherapy followed
by hematopoietic stem cell transplantation (HSCT).
George et al. previously reported long-term results from
high-risk neuroblastoma cases treated with induction
chemotherapy and local control measures followed by au-
tologous PBSCT [12]; these authors concluded that tan-
dem PBSCT could be safely performed in these patients
and that it improved long-term survival. Unfortunately, al-
though our patients’ relapsed lesions temporarily regressed
after HSCT treatment, all three patients showed disease
progression within 1 year of treatment and died of their
disease. Previous reports have also demonstrated a poor
prognosis with intrathoracic MNT [3,4,13,14]. Although
complete resection is a necessary and potentially curative
therapeutic modality for intrathoracic MNT, the prognosis
following resection was unsatisfactory in our cases. In
addition to local control, the establishment of a strategy to
control systemic disease is required, as is the case with
other high-risk soft tissue sarcomas.
The clinical characteristics of our three patients with in-
trathoracic MNTs were compared with those of patients
with intrathoracic BNTs resected at our institution during
the same time period (Table 1). Patients having MNT
were younger compared with patients having BNT, al-
though the BNT group also included a young adult pa-
tient. Other clinical features, including symptoms, tumor
size, and invasiveness of the tumor, did not differ between
the groups. Generally, greater tumor size, involvement of
adjacent bony structures, and intraspinal extension are
known to be signs of a MNT [1]. In the previously re-
ported imaging analysis, size, surface characteristics, and
internal heterogeneity of the lesion were reported to have
predictive value of malignancy [15,16]. MRI has advantage
in evaluating invasiveness to the neighboring organs and
internal characteristics of the lesion. On the other hand,
CT is superior in describing the tumor surface and vascu-
larity. However, two of the three MNTs in this report were
surgically excised without the combined resection of adja-
cent structures. Interestingly, the tumor with the most ag-
gressive growth was the smallest in size among our three
cases when detected. On the other hand, large-sized
tumor or tumor with intraspinal extension was included
in the BNT group of our study. In our experience with in-
trathoracic neurogenic tumors, we have not been able to
differentiate MNTs from BNTs prior to resection.
Five of seven patients with BNT receiving FDG-PET/
CT had abnormal FDG uptake in our study. Because the
findings of FDG-PET/CT between MNT and BNT were
not compared, we could not lead to the answer about the
usefulness of the FDG-PET/CT. In the previous study,
Cardona et al. reported the differences of the FDG uptake
between BNT and MNT [17]. Although it may be useful
to discriminate between MNT and BNT, further analysis
is necessary.
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We have presented three cases with intrathoracic MNT.
Although all three lesions were completely excised, each
of the patients developed recurrence and ultimately died
of the disease. The clinical differentiation of MNTs from
BNTs was difficult before treatment.
Consent
Before operation, we obtained general consent from every
patient for using their clinical data for some clinical stud-
ies. However, the written informed consent for this case
report was not obtained from the patients because this re-
port is just retrospective case report without additional in-
vasive examinations or treatments for the study.
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